Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | APP | P05067 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | QPCT | Q16769 | 1/20 | 0.49 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27986449 | 0.81 | ALDH1A1 (0.47) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1180159 | 0.80 | APP (0.57) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6134626 | 0.80 | RAB9A (0.72) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3500308 | 0.79 | CSNK2A1 (0.59) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27986683 | 0.79 | QPCT (0.62) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12091997 | 0.79 | CSNK2A1 (0.62) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1747919 | 0.79 | KMT2A (0.58) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22684975 | 0.78 | NPC1 (0.57) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22684972 | 0.78 | SMN1; SMN2 (0.60) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18456844 | 0.77 | APP (0.53) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-14 | — | — | US | disclosed |
| US-20150342935-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-12-03 | — | — | US | disclosed |
| EP-2271650-B1 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-02 | — | — | US | disclosed |
| US-20140221377-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL MYERS SQUIBB CO (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130131064-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-23 | — | — | US | disclosed |
| US-8309577-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2493892-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120035178-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-09 | — | — | US | disclosed |
| US-20120035189-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-09 | — | — | US | disclosed |
| CN-101659661-A | 2-aryl-3-(tetrahydro-2H-pyran-4-yl)-N-aryl-heterocyclic-propionamide compound, medicinal composition thereof and application thereof | SHANGHAI INST MATERIA MEDICA | 2010-03-03 | — | — | CN | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| WO-2009131926-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-29 | — | — | WO | disclosed |
| EP-1299381-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| WO-2002000649-A9 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
| US-20060046987-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2006-03-02 | — | — | US | disclosed |
| US-6919338-B2 | Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase | ASTRAZENECA AB (SE) | 2005-07-19 | — | — | US | disclosed |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | US | disclosed |
| EP-1299381-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002000649-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035189-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | MAPT 268/4885ALDH1A1 1082/4885NPC1 896/4885 |
| US-20120035178-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | MAPT 268/4885ALDH1A1 1082/4885NPC1 896/4885 |
| US-20140221377-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | MAPT 268/4885ALDH1A1 1082/4885NPC1 896/4885 |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | MAPT 268/4885ALDH1A1 1082/4885NPC1 896/4885 |
| US-20130131064-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | MAPT 268/4885ALDH1A1 1082/4885NPC1 896/4885 |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | MAPT 268/4885ALDH1A1 1082/4885NPC1 896/4885 |
| US-20150342935-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | MAPT 268/4885ALDH1A1 1082/4885NPC1 896/4885 |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | MAPT 268/4885ALDH1A1 1082/4885NPC1 896/4885 |
| US-20060046987-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKB, AURKC | MAPT 1921/4885ALDH1A1 4418/4885NPC1 2593/4885 |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKC, AURKB | MAPT 1809/4885ALDH1A1 4009/4885NPC1 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.